Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 16/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29576385 | 1.00 | GRM5 (1.00) | GRM5 | |
| SCHEMBL4320888 | 0.87 | GRM5 (0.76) | GRM5 | |
| SCHEMBL4337120 | 0.87 | GRM5 (0.76) | GRM5 | |
| SCHEMBL4342402 | 0.86 | GRM5 (0.74) | GRM5 | |
| SCHEMBL4337164 | 0.86 | GRM5 (0.74) | GRM5 | |
| SCHEMBL4339146 | 0.86 | GRM5 (0.74) | GRM5 | |
| SCHEMBL4332923 | 0.86 | GRM5 (0.74) | GRM5 | |
| SCHEMBL8247045 | 0.86 | GRM5 (0.74) | GRM5 | |
| SCHEMBL4332879 | 0.85 | GRM5 (0.73) | GRM5 | |
| SCHEMBL4329840 | 0.84 | GRM5 (0.71) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023279193-A9 | PHOSPHODIESTERASE INHIBITORS FOR THE MITIGATION OF FRAGILE X SYNDROME SYMPTOMS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2023-04-27 | — | — | WO | claimed |
| US-20090227582-A1 | Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-09-10 | — | — | US | claimed |
| US-7550482-B2 | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-06-23 | — | — | US | claimed |
| EP-1931635-A1 | TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Merz Pharma GmbH & Co.KGaA (DE) | 2008-06-18 | — | — | EP | claimed |
| WO-2007023290-A1 | TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-03-01 | — | — | WO | claimed |
| US-20050288284-A1 | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-12-29 | — | — | US | claimed |
| EP-4366739-A1 | PHOSPHODIESTERASE INHIBITORS FOR THE MITIGATION OF FRAGILE X SYNDROME SYMPTOMS | The Royal Institution for the Advancement of Learning / McGill University (CA) | 2024-05-15 | — | — | EP | disclosed |
| WO-2023279193-A9 | PHOSPHODIESTERASE INHIBITORS FOR THE MITIGATION OF FRAGILE X SYNDROME SYMPTOMS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023279193-A2 | PHOSPHODIESTERASE INHIBITORS FOR THE MITIGATION OF FRAGILE X SYNDROME SYMPTOMS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2023-01-12 | — | — | WO | disclosed |
| US-11033545-B2 | Negative allosteric modulators of MGLUR5 for use in the treatment of mature brain damages | Sinntaxis AB (SE) | 2021-06-15 | — | — | US | disclosed |
| US-20090227582-A1 | Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-09-10 | — | — | US | disclosed |
| US-20090227582-A1 | Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-09-10 | — | — | US | disclosed |
| US-7550482-B2 | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-06-23 | — | — | US | disclosed |
| US-7550482-B2 | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-06-23 | — | — | US | disclosed |
| EP-1931635-A1 | TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Merz Pharma GmbH & Co.KGaA (DE) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007023242-A1 | TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007023242-A1 | TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007023290-A1 | TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007023290-A1 | TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-03-01 | — | — | WO | disclosed |
| US-20050288284-A1 | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11033545-B2 | Negative allosteric modulators of MGLUR5 for use in the treatment of mature brain damages | GRM5, GRIK5, GRM1 | GRM5 1/4885 |
| US-20090227582-A1 | Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors | GRM1, GRM5, GRM2 | GRM5 2/4885 |
| US-20050288284-A1 | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors | GRM1, GRM5, GRM2 | GRM5 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.